Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients

Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women

(2016) Anna H. Tran et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications

(2016) Catia Marzolini et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pregnancy affects nevirapine pharmacokinetics

(2016) Adeniyi Olagunju et al.   Pharmacogenetics and Genomics

Using Lopinavir Concentrations in Hair Samples to Assess Treatment Outcomes on Second-Line Regimens Among Asian Children

(2015) Wasana Prasitsuebsai et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects

(2015) Ahmed Hamed Salem et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study

(2015) L Dickinson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacokinetics of tenofovir during pregnancy and postpartum

(2015) BM Best et al.   HIV MEDICINE

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study

(2015)   LANCET INFECTIOUS DISEASES

Pharmacokinetics of drugs in pregnancy

(2015) Maisa Feghali et al.   SEMINARS IN PERINATOLOGY

Is it time to revise antiretrovirals dosing? A pharmacokinetic viewpoint

(2014) Dario Cattaneo et al.   AIDS

Randomized Clinical Trial Comparing the Pharmacokinetics of Standard- and Increased-Dosage Lopinavir-Ritonavir Coformulation Tablets in HIV-Positive Pregnant Women

(2014) M. Santini-Oliveira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Novel Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Detection of Anti-HIV Drugs Lopinavir, Ritonavir, and Tenofovir in Plasma

(2014) J. Koehn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Intracellular Antiviral Activity of Low-Dose Ritonavir in Boosted Protease Inhibitor Regimens

(2014) Amedeo De Nicolò et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients

(2014) A. Calcagno et al.   ANTIVIRAL RESEARCH

Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers

(2014) Thomas N. Kakuda et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

(2014) A. Castagna et al.   JOURNAL OF INFECTIOUS DISEASES

Therapeutic drug monitoring of intracellular anti-infective agents

(2014) Antonio D’Avolio et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Common clinical conditions – age, low BMI, ritonavir use, mild renal impairment – affect tenofovir pharmacokinetics in a large cohort of HIV-infected women

(2013) Sanjiv M. Baxi et al.   AIDS

Short Communication: Aging Not Gender Is Associated with High Atazanavir Plasma Concentrations in Asian HIV-Infected Patients

(2013) Anchalee Avihingsanon et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Adherence Profiles and Therapeutic Responses of Treatment-Naive HIV-Infected Patients Starting Boosted Atazanavir-Based Therapy in the ANRS 134-COPHAR 3 Trial

(2013) Jean-Jacques Parienti et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Viral Suppression Following Switch to Second-line Antiretroviral Therapy: Associations With Nucleoside Reverse Transcriptase Inhibitor Resistance and Subtherapeutic Drug Concentrations Prior to Switch

(2013) Victoria Johnston et al.   JOURNAL OF INFECTIOUS DISEASES

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results

(2013) Joel E. Gallant et al.   JOURNAL OF INFECTIOUS DISEASES

Plasma Concentrations of Efavirenz and Nevirapine among HIV-Infected Patients with Immunological Failure Attending a Tertiary Hospital in North-Western Tanzania

(2013) Daniel W. Gunda et al.   PLoS One

Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability

(2013) Iris Usach et al.   Journal of the International AIDS Society

The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women

(2012) Angela P.H. Colbers et al.   AIDS

Nevirapine Exposure with WHO Pediatric Weight Band Dosing: Enhanced Therapeutic Concentrations Predicted Based on Extensive International Pharmacokinetic Experience

(2012) Mina Nikanjam et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Free and total plasma levels of lopinavir during pregnancy, at delivery and in postpartum: implication for dosage adjustments in pregnant women

(2012) Aurélie Fayet-Mello et al.   ANTIVIRAL THERAPY

Pharmacokinetic Optimization of Antiretroviral Therapy in Pregnancy

(2012) Kajal Buckoreelall et al.   CLINICAL PHARMACOKINETICS

Evaluation of Saliva as an Alternative Matrix for Monitoring Plasma Zidovudine, Lamivudine and Nevirapine Concentrations in Rwanda

(2012) Alain Gras et al.   CURRENT HIV RESEARCH

Therapeutic Drug Monitoring in Pregnancy

(2012) Doreen M. Matsui   THERAPEUTIC DRUG MONITORING

Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation

(2011) Marta Boffito et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Atazanavir Concentration in Hair Is the Strongest Predictor of Outcomes on Antiretroviral Therapy

(2011) M. Gandhi et al.   CLINICAL INFECTIOUS DISEASES

A Randomized Clinical Trial Evaluating Therapeutic Drug Monitoring (TDM) for Protease Inhibitor–Based Regimens in Antiretroviral-Experienced HIV-Infected Individuals: Week 48 Results of the A5146 Study

(2011) Mary Albrecht et al.   HIV CLINICAL TRIALS

Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women*

(2011) P Izurieta et al.   HIV MEDICINE

Atazanavir Pharmacokinetics With and Without Tenofovir During Pregnancy

(2011) Mark Mirochnick et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

The Role of Therapeutic Drug Monitoring in the Management of Patients With Human Immunodeficiency Virus Infection

(2011) Erina Pretorius et al.   THERAPEUTIC DRUG MONITORING

Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations

(2010) Sonia Rodríguez-Nóvoa et al.   AIDS

Population Pharmacokinetics of Nevirapine in HIV-1-Infected Pregnant Women and Their Neonates

(2010) Sihem Benaboud et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients

(2010) José Moltó et al.   ANTIVIRAL THERAPY

Therapeutic drug monitoring in highly active antiretroviral therapy

(2010) Xia Liu et al.   Expert Opinion On Drug Safety

Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection

(2010) M Fabbiani et al.   HIV MEDICINE

Suboptimal Nevirapine Steady-State Pharmacokinetics During Intrapartum Compared With Postpartum in HIV-1-Seropositive Ugandan Women

(2010) Mohammed Lamorde et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens

(2010) D. Gonzalez de Requena et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The Role of Therapeutic Drug Monitoring in Pediatric HIV/AIDS

(2010) David M Burger   THERAPEUTIC DRUG MONITORING

Protease inhibitor levels in hair strongly predict virologic response to treatment

(2009) Monica Gandhi et al.   AIDS

A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients

(2009) Lisa M Demeter et al.   AIDS

Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda

(2009) Laurence Ahoua et al.   BMC INFECTIOUS DISEASES

Raltegravir: The First HIV Type 1 Integrase Inhibitor

(2009) Charles Hicks et al.   CLINICAL INFECTIOUS DISEASES

Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action

(2009) Caroline Bazzoli et al.   CLINICAL PHARMACOKINETICS

Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity

(2009) A A Mathias et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacokinetics and drug metabolism in the elderly

(2009) Ulrich Klotz   DRUG METABOLISM REVIEWS

Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen - ANRS 111 trial

(2009) Xavier Duval et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Pharmacokinetics of low-dose protease inhibitors and efavirenz in low- and middle-income countries

(2009) Meena Gorowara et al.   Current Opinion in HIV and AIDS

Overview of Therapeutic Drug Monitoring

(2009) Ju-Seop Kang et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

Predictive Values of the Human Immunodeficiency Virus Phenotype and Genotype and of Amprenavir and Lopinavir Inhibitory Quotients in Heavily Pretreated Patients on a Ritonavir-Boosted Dual-Protease-Inhibitor Regimen

(2008) A. Barrail-Tran et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Darunavir Inhibitory Quotient Predicts the 48-Week Virological Response to Darunavir-Based Salvage Therapy in Human Immunodeficiency Virus-Infected Protease Inhibitor-Experienced Patients

(2008) J. Molto et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Low Dose of Ritonavir-Boosted Atazanavir Provides Adequate Pharmacokinetic Parameters in HIV-1-Infected Thai Adults

(2008) A Avihingsanon et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Antiepileptic drugsbest practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies

(2008) Philip N. Patsalos et al.   EPILEPSIA

Pharmacologic Consideration for the Use of Antiretroviral Agents in the Elderly

(2008) Martin S. Rhee et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Single-Measurement Therapeutic Drug Monitoring of the HIV/AIDS Drugs Abacavir, Zidovudine, Lamivudine, Efavirenz, Nevirapine, Lopinavir and Nelfinavir

(2008) Josef Donnerer et al.   PHARMACOLOGY

Use of therapeutic drug monitoring in HIV disease

(2008) Matthijs van Luin et al.   Current Opinion in HIV and AIDS

Inhibitory quotient in HIV pharmacology

(2008) Charles la Porte   Current Opinion in HIV and AIDS

Greater Tenofovir‐Associated Renal Function Decline with Protease Inhibitor–Based versus Nonnucleoside Reverse‐Transcriptase Inhibitor–Based Therapy

(2007) Miguel Goicoechea et al.   JOURNAL OF INFECTIOUS DISEASES